Search

… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … “The visual field improvements observed indicate that RNA therapy could potentially be used to treat early stage …

… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … trial and is a first-in-class investigational RNA therapy designed to address the underlying cause of Leber …

… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the … Sirius and Celeste clinical trials of investigational RNA therapy QR-421a for people with USH2A mediated retinitis …

… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … Sepofarsen Sepofarsen (QR-110) is an investigational RNA therapy designed to restore vision in Leber congenital …

… highlights significant potential of ProQR’s Axiomer ® RNA base-editing platform and strengthens financial position … to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … trial and is a first-in-class investigational RNA therapy designed to address the underlying cause of Leber …

… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … and we are pleased to partner with them, aiming to bring a therapy to patients in an area of unmet need for a …

… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced a … Title:  Phase 1b/2 interim results of QR-421a RNA therapy in retinitis pigmentosa due to mutations in the USH2A …

… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … Phase 1b/2 trial results of intravitreal sepofarsen RNA therapy in Leber congenital amaurosis 10 (LCA10) Presenter: …

… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … Phase 1b/2 trial results of intravitreal sepofarsen RNA therapy in Leber congenital amaurosis 10 (LCA10) Presenter: …

… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … amaurosis 10 (LCA10) and the investigational RNA therapy for LCA10, sepofarsen experience to date. The call …